NEW DELHI:(Economy india): India’s pharmaceutical industry needs to move beyond its traditional strength in cost-effective generic medicines and focus more on innovation, advanced manufacturing, quality and global regulatory standards to unlock its full growth potential, industry experts said.
With India targeting a pharmaceutical market of USD 130 billion by 2030, experts said the sector must increase investments in research and development, digital technologies and advanced manufacturing capabilities.
The discussions were held ahead of the 19th edition of CPHI & PMEC India 2026, scheduled to take place in November across venues in Delhi-NCR.
Experts highlighted that while India remains a major global supplier of generic medicines, future growth will increasingly depend on developing innovative drugs, improving manufacturing technologies and meeting stringent international quality standards.
Greater adoption of digital technologies and expansion of contract research and development manufacturing could also help Indian pharmaceutical companies strengthen their position in global markets.
The industry is expected to play a larger role in emerging areas such as complex generics, biotechnology, advanced therapies and specialised pharmaceutical manufacturing. Experts said sustained investment in innovation and quality would be crucial for India to compete with leading pharmaceutical markets worldwide.
The shift from a cost-driven model to an innovation- and quality-focused ecosystem could therefore become a key factor in achieving India’s ambitious pharmaceutical growth targets by 2030.
(Economy india)
